Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Nuvation Bio participates in a conference call with Jefferies » 11:18
04/19/21
04/19
11:18
04/19/21
11:18
NUVB

Nuvation Bio

$11.14 /

-0.21 (-1.85%)

Healthcare Analyst Yee…

Healthcare Analyst Yee holds a conference call with management on April 19 at 12 pm hosted by Jefferies.

ShowHide Related Items >><<
NUVB Nuvation Bio
$11.14 /

-0.21 (-1.85%)

NUVB Nuvation Bio
$11.14 /

-0.21 (-1.85%)

04/06/21
Fly Intel: Top five analyst initiations
04/06/21 RBC Capital
Nuvation Bio initiated with an Outperform at RBC Capital
03/08/21 Jefferies
Nuvation Bio initiated with a Buy at Jefferies
03/08/21 Cowen
Nuvation Bio initiated with an Outperform at Cowen
Over a month ago
Initiation
Fly Intel: Top five analyst initiations » 09:53
04/06/21
04/06
09:53
04/06/21
09:53
MCD

McDonald's

$229.22 /

+0.28 (+0.12%)

, YUM

Yum! Brands

$111.80 /

+1.14 (+1.03%)

, SBUX

Starbucks

$111.46 /

+0.46 (+0.41%)

, YUMC

Yum China

$59.55 /

+0.36 (+0.61%)

, GNOG

Golden Nugget Online

$15.30 /

+1.51 (+10.95%)

, CELH

Celsius Holdings

$52.31 /

+0.49 (+0.95%)

, YETI

Yeti

$74.06 /

+1.14 (+1.56%)

, NUVB

Nuvation Bio

$10.60 /

-0.24 (-2.21%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. McDonald's (MCD) and Yum! Brands (YUM) initiated with a Neutral at Atlantic Equities, with Starbucks (SBUX) and Yum China (YUMC) initiated with an Overweight at Atlantic Equities. 2. Golden Nugget Online (GNOG) initiated with a Buy at Jefferies. 3. Celsius Holdings (CELH) initiated with a Neutral at Credit Suisse. 4. Yeti (YETI) initiated with an Outperform at Credit Suisse. 5. Nuvation Bio (NUVB) initiated with an Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
YUMC Yum China
$59.55 /

+0.36 (+0.61%)

YUM Yum! Brands
$111.80 /

+1.14 (+1.03%)

YETI Yeti
$74.06 /

+1.14 (+1.56%)

SBUX Starbucks
$111.46 /

+0.46 (+0.41%)

NUVB Nuvation Bio
$10.60 /

-0.24 (-2.21%)

MCD McDonald's
$229.22 /

+0.28 (+0.12%)

GNOG Golden Nugget Online
$15.30 /

+1.51 (+10.95%)

CELH Celsius Holdings
$52.31 /

+0.49 (+0.95%)

MCD McDonald's
$229.22 /

+0.28 (+0.12%)

04/06/21 Atlantic Equities
Atlantic Equities starts McDonald's at Neutral with $237 price target
04/06/21 Atlantic Equities
McDonald's initiated with a Neutral at Atlantic Equities
03/17/21
Fly Intel: Top five analyst upgrades
03/17/21 Deutsche Bank
McDonald's upgraded to Buy on estimate upside potential at Deutsche Bank
YUM Yum! Brands
$111.80 /

+1.14 (+1.03%)

04/06/21 Atlantic Equities
Atlantic Equities starts Yum! Brands at Neutral with $118 price target
04/06/21 Atlantic Equities
Yum! Brands initiated with a Neutral at Atlantic Equities
03/02/21 Citi
Citi upgrades Beyond Meat to Buy with 'new-found enthusiasm' for long-term story
02/22/21 Wells Fargo
Wells Fargo strategist upgrades Consumer Services sector to Overweight
SBUX Starbucks
$111.46 /

+0.46 (+0.41%)

04/06/21 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
03/19/21
Fly Intel: Top five analyst upgrades
03/19/21 Wedbush
Starbucks upgraded to Outperform from Neutral at Wedbush
03/19/21 Wedbush
Starbucks upgraded to Outperform from Neutral at Wedbush
YUMC Yum China
$59.55 /

+0.36 (+0.61%)

04/06/21 Atlantic Equities
Atlantic Equities starts Yum China at Overweight, names as a top pick
04/06/21 Atlantic Equities
Yum China initiated with an Overweight at Atlantic Equities
01/26/21 Jefferies
Yum China price target raised to $68.70 from $63.10 at Jefferies
11/02/20 Citi
Yum China price target raised to $71.30 from $60.15 at Citi
GNOG Golden Nugget Online
$15.30 /

+1.51 (+10.95%)

04/06/21 Jefferies
Golden Nugget Online initiated with a Buy at Jefferies
03/24/21 Benchmark
Golden Nugget Online price target lowered to $24 from $27 at Benchmark
01/13/21 Benchmark
Golden Nugget Online initiated with a Buy at Benchmark
CELH Celsius Holdings
$52.31 /

+0.49 (+0.95%)

04/06/21 Credit Suisse
Celsius Holdings initiated with a Neutral at Credit Suisse
03/11/21 Ladenburg
Celsius Holdings upgraded to Buy at Ladenburg following quarterly results
03/11/21 Ladenburg
Celsius Holdings upgraded to Buy from Neutral at Ladenburg
02/10/21 B. Riley
Celsius Holdings price target raised to $73 from $40 at B. Riley Securities
YETI Yeti
$74.06 /

+1.14 (+1.56%)

04/06/21 Credit Suisse
Yeti initiated with an Outperform at Credit Suisse
02/12/21
Fly Intel: Top five analyst upgrades
02/12/21 Citi
Yeti upgraded to Buy from Neutral at Citi
02/12/21 Piper Sandler
Yeti price target raised to $95 from $91 at Piper Sandler
NUVB Nuvation Bio
$10.60 /

-0.24 (-2.21%)

04/06/21 RBC Capital
Nuvation Bio initiated with an Outperform at RBC Capital
03/08/21 Jefferies
Nuvation Bio initiated with a Buy at Jefferies
03/08/21 Cowen
Nuvation Bio initiated with an Outperform at Cowen
03/08/21 Wedbush
Wedbush bullish on Nuvation Bio, initiates with an Outperform
YUMC Yum China
$59.55 /

+0.36 (+0.61%)

YUM Yum! Brands
$111.80 /

+1.14 (+1.03%)

YETI Yeti
$74.06 /

+1.14 (+1.56%)

SBUX Starbucks
$111.46 /

+0.46 (+0.41%)

MCD McDonald's
$229.22 /

+0.28 (+0.12%)

GNOG Golden Nugget Online
$15.30 /

+1.51 (+10.95%)

CELH Celsius Holdings
$52.31 /

+0.49 (+0.95%)

  • 04
    Sep
  • 28
    May
  • 11
    May
YETI Yeti
$74.06 /

+1.14 (+1.56%)

SBUX Starbucks
$111.46 /

+0.46 (+0.41%)

MCD McDonald's
$229.22 /

+0.28 (+0.12%)

CELH Celsius Holdings
$52.31 /

+0.49 (+0.95%)

YUMC Yum China
$59.55 /

+0.36 (+0.61%)

YUM Yum! Brands
$111.80 /

+1.14 (+1.03%)

YETI Yeti
$74.06 /

+1.14 (+1.56%)

SBUX Starbucks
$111.46 /

+0.46 (+0.41%)

MCD McDonald's
$229.22 /

+0.28 (+0.12%)

GNOG Golden Nugget Online
$15.30 /

+1.51 (+10.95%)

CELH Celsius Holdings
$52.31 /

+0.49 (+0.95%)

YETI Yeti
$74.06 /

+1.14 (+1.56%)

SBUX Starbucks
$111.46 /

+0.46 (+0.41%)

MCD McDonald's
$229.22 /

+0.28 (+0.12%)

GNOG Golden Nugget Online
$15.30 /

+1.51 (+10.95%)

CELH Celsius Holdings
$52.31 /

+0.49 (+0.95%)

Initiation
Nuvation Bio initiated with an Outperform at RBC Capital » 08:20
04/06/21
04/06
08:20
04/06/21
08:20
NUVB

Nuvation Bio

$10.84 /

+0.67 (+6.59%)

RBC Capital analyst Mark…

RBC Capital analyst Mark Dwelle initiated coverage of Nuvation Bio with an Outperform rating and $15 price target. The analyst is positive on the company's "strong" management team and capital position, which should enable its "expeditious" development of its novel anti-cancer agent pipeline with key phase 1 catalysts approaching at the end of 2021 and in 2022. Nuvation's lead asset NUV-422 offers a "differentiated" potential best-in-class agent based on brain penetrance and improved target exposure, Dwelle tells investors in a research note.

ShowHide Related Items >><<
NUVB Nuvation Bio
$10.84 /

+0.67 (+6.59%)

NUVB Nuvation Bio
$10.84 /

+0.67 (+6.59%)

03/08/21 Jefferies
Nuvation Bio initiated with a Buy at Jefferies
03/08/21 Cowen
Nuvation Bio initiated with an Outperform at Cowen
03/08/21 Wedbush
Wedbush bullish on Nuvation Bio, initiates with an Outperform
03/08/21 Wedbush
Nuvation Bio initiated with an Outperform at Wedbush
Syndicate
Nuvation Bio files to sell 60.9M shares of common stock for holders  17:11
03/11/21
03/11
17:11
03/11/21
17:11
NUVB

Nuvation Bio

$13.88 /

+0.905 (+6.98%)

 
ShowHide Related Items >><<
NUVB Nuvation Bio
$13.88 /

+0.905 (+6.98%)

NUVB Nuvation Bio
$13.88 /

+0.905 (+6.98%)

03/08/21 Jefferies
Nuvation Bio initiated with a Buy at Jefferies
03/08/21 Cowen
Nuvation Bio initiated with an Outperform at Cowen
03/08/21 Wedbush
Wedbush bullish on Nuvation Bio, initiates with an Outperform
03/08/21 Wedbush
Nuvation Bio initiated with an Outperform at Wedbush
Hot Stocks
Nuvation Bio announces FDA orphan drug designation for NUV-422 » 07:04
03/11/21
03/11
07:04
03/11/21
07:04
NUVB

Nuvation Bio

$12.98 /

+0.2 (+1.56%)

Nuvation Bio announced…

Nuvation Bio announced that the U.S. FDA has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase 2/4/6 inhibitor, for the treatment of patients with malignant gliomas.

ShowHide Related Items >><<
NUVB Nuvation Bio
$12.98 /

+0.2 (+1.56%)

03/08/21 Jefferies
Nuvation Bio initiated with a Buy at Jefferies
03/08/21 Cowen
Nuvation Bio initiated with an Outperform at Cowen
03/08/21 Wedbush
Wedbush bullish on Nuvation Bio, initiates with an Outperform
03/08/21 Wedbush
Nuvation Bio initiated with an Outperform at Wedbush
Initiation
Nuvation Bio initiated with a Buy at Jefferies » 08:09
03/08/21
03/08
08:09
03/08/21
08:09
NUVB

Nuvation Bio

$10.86 /

+0.36 (+3.43%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee initiated coverage of Nuvation Bio with a Buy rating and $20 price target. The company has "elegant chemistry in multiple high-value cancer area," said Yee, who notes Nuvation has five different cancer programs all with data over the next few years. The company's NUV-422 is "a differentiated and improved" CDK 2/4/6 for glioblastoma and breast cancer that "could move fast," said Yee, who adds that Nuvation may file up to five Investigational New Drug applications over the next six years.

ShowHide Related Items >><<
NUVB Nuvation Bio
$10.86 /

+0.36 (+3.43%)

03/08/21 Cowen
Nuvation Bio initiated with an Outperform at Cowen
03/08/21 Wedbush
Wedbush bullish on Nuvation Bio, initiates with an Outperform
03/08/21 Wedbush
Nuvation Bio initiated with an Outperform at Wedbush
03/08/21 BTIG
Nuvation Bio initiated with a Buy at BTIG
Initiation
Nuvation Bio initiated with an Outperform at Cowen » 07:36
03/08/21
03/08
07:36
03/08/21
07:36
NUVB

Nuvation Bio

$10.86 /

+0.36 (+3.43%)

Cowen analyst Yaron Weber…

Cowen analyst Yaron Weber initiated coverage of Nuvation Bio with an Outperform rating. The analyst said its proven management team is building a deep pipeline focusing on novel and validated oncogenic pathways. He anticipates development for mBC and patients with brain metastases and with a deep pipeline poised for Five INDs in six years, he is bullish on the shares.

ShowHide Related Items >><<
NUVB Nuvation Bio
$10.86 /

+0.36 (+3.43%)

03/08/21 Wedbush
Wedbush bullish on Nuvation Bio, initiates with an Outperform
03/08/21 Wedbush
Nuvation Bio initiated with an Outperform at Wedbush
03/08/21 BTIG
Nuvation Bio initiated with a Buy at BTIG
03/08/21 BMO Capital
Nuvation Bio initiated with an Outperform at BMO Capital
Initiation
Wedbush bullish on Nuvation Bio, initiates with an Outperform » 07:23
03/08/21
03/08
07:23
03/08/21
07:23
NUVB

Nuvation Bio

$10.86 /

+0.36 (+3.43%)

As previously reported,…

As previously reported, Wedbush analyst David Nierengarten initiated coverage of Nuvation Bio with an Outperform rating and $20 price target. The analyst notes that the company's lead program NUV-422 is a cyclin-dependent kinase 2/4/6 inhibitor currently in a Phase 1/2 study for recurrent/refractory high-grade gliomas. Initial data from the Phase 1 portion of the study are expected in 2022 and Nuvation Bio intends to initiate additional studies for the program throughout 2022 including in brain metastases, ER-positive metastatic breast cancer, and metastatic castrationresistant prostate cancer, he adds. Nierengarten projects the program could achieve over $3B in worldwide revenues by 2028 assuming success.

ShowHide Related Items >><<
NUVB Nuvation Bio
$10.86 /

+0.36 (+3.43%)

03/08/21 Wedbush
Nuvation Bio initiated with an Outperform at Wedbush
03/08/21 BTIG
Nuvation Bio initiated with a Buy at BTIG
03/08/21 BMO Capital
Nuvation Bio initiated with an Outperform at BMO Capital
Initiation
Nuvation Bio initiated with an Outperform at Wedbush » 06:29
03/08/21
03/08
06:29
03/08/21
06:29
NUVB

Nuvation Bio

$10.86 /

+0.36 (+3.43%)

Wedbush initiated…

Wedbush initiated coverage of Nuvation Bio with an Outperform rating and $20 price target.

ShowHide Related Items >><<
NUVB Nuvation Bio
$10.86 /

+0.36 (+3.43%)

03/08/21 BTIG
Nuvation Bio initiated with a Buy at BTIG
03/08/21 BMO Capital
Nuvation Bio initiated with an Outperform at BMO Capital
Initiation
Nuvation Bio initiated with a Buy at BTIG » 05:45
03/08/21
03/08
05:45
03/08/21
05:45
NUVB

Nuvation Bio

$10.86 /

+0.36 (+3.43%)

BTIG analyst Thomas…

BTIG analyst Thomas Shrader initiated coverage of Nuvation Bio with a Buy rating and $16 price target. Nuvation is a clinical-stage oncology company with multiple small molecule drug candidates designed to improve on standard of care regimens via more precise targeting, Shrader tells investors in a research note.

ShowHide Related Items >><<
NUVB Nuvation Bio
$10.86 /

+0.36 (+3.43%)

03/08/21 BMO Capital
Nuvation Bio initiated with an Outperform at BMO Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.